{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT00880412: Phase 2 Interventional Completed Alzheimer's Disease
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Etazolate (EHT-0202) is a selective, positive GABAA receptor modulator has completed phase II clinical trials in patients with Alzheimer's disease. It is also a selective phosphodiesterase-4 inhibitor that is specific for cAMP. Etazolate showed anxiolytic and antidepressant activity and could be useful in managing post-traumatic stress disorder.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Talibegron (ZD2079) is a β3 adrenoceptor agonist and insulin sensitiser. It was developed as a potential treatment for obesity and non-insulin-dependent diabetes mellitus. Talibegron hydrochloride had been in phase II clinical trials by AstraZeneca for the treatment of type 2 diabetes and obesity. However, this research has been discontinued.
Status:
Investigational
Source:
INN:pararosaniline embonate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Pararosaniline pamoate (CI 403-A) was developed as an orally active drug for the treatment of Schistosoma japonicum infection. The clinical trial has shown that capsules were safe and effective; in addition, this drug was well tolerated with a minimum of side effects, which were mostly mild and transient and did not require interruption of treatment. Besides, pararosaniline pamoate was an inhibitor of E.histolytica Hsp90 (EhHsp90) with promising activity against the parasite Pararosaniline pamoate, that causes amebiasis worldwide. Information about the current use of this drug is not available.
Class (Stereo):
CHEMICAL (UNKNOWN)
Furcloprofen was developed as an analgesic agent with anti-inflammatory properties. Information about the current use of this compound is not available.
Status:
Investigational
Source:
INN:pirinixic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Pirinixic acid is a PPARα ligand that can affect atherogenesis by modulating hepatic lipid metabolism and by acting directly on vascular tissue. PPARα activation is generally assumed to be the primary means by which Pirinixic acid produces its biological effects. Nevertheless, there is increasing evidence to suggest that Pirinixic acid is also capable of affecting cellular processes directly. It is under experimental investigation for prevention of severe cardiac dysfunction, cardiomyopathy and heart failure as a result of lipid accumulation within cardiac myocytes. Treatment is primarily aimed at individuals with an adipose triglyceride lipase (ATGL) enzyme deficiency or mutation. For example, cardiac contractility was improved by treating ATGL(-/-) mice with the Pirinixic acid.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Ethoxazene (2,4-diamino-4-ethoxyazobenzene) is an analgesic compound. It may be used as an indicator of acidity in an examination of gastric function.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Flunoprost is a prostaglandin analog. Flunoprost has been used to treat platelet-activating factor-induced shock and to prolong skin allograft survival in mouse models.
Status:
Investigational
Source:
NCT00766324: Phase 2 Interventional Completed Metastatic Hormone Refractory Prostate Cancer
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Danusertib is a serine/threonine kinase inhibitor of multiple kinases, including aurora-A, B, and C. It also inhibits several cancer related tyrosine kinases as well as Abl, Trk-a, fibroblast growth receptor-1 and Ret. Danusertib is in phase II trials for the treatment of solid tumours, prostate cancer and chronic myeloid leukemia (CML). The most frequently reported side effects were neutropenia, nausea, anorexia, fatigue, and diarrhea.
Class (Stereo):
CHEMICAL (RACEMIC)
THIALBARBITAL is a barbiturate derivative with sedative effects. Barbiturates have hypnotic properties and are used as active moiety on central nervous system. Thialbarbital was synthesized in the 1960s. It was used primarily as a surgical anesthesia. Thialbarbital causes marked depression of the activity of the reticular formation and only slight depression of cortical activity. Thialbarbital is short acting and has less of a tendency to induce respiratory depression than other barbiturate derivatives such as pentobarbital.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Telupidine (GR53992B), a dihydropyridine derivative is a calcium channel blocker. This is an antihypertensive and cardiovascular agent. Information about the current use of this compound is not available.
